Do, 8. Juni 2023, 20:41 Uhr

Vertex Pharmaceuticals

WKN: 882807 / ISIN: US92532F1003

Kann man die Aktie in D handeln?

eröffnet am: 22.02.04 22:17 von: Biomedi
neuester Beitrag: 06.11.07 13:06 von: imigran
Anzahl Beiträge: 8
Leser gesamt: 9412
davon Heute: 1

bewertet mit 0 Sternen

22.02.04 22:17 #1  Biomedi
Kann man die Aktie in D handeln? Vertex Drug Reverses Cancer in Animal Study  
Sun Feb 22, 1:04 PM ET  Add Health - Reuters to My Yahoo!

NEW YORK (Reuters) - A new type of cancer drug stopped tumor growth in an early animal study, boosting hopes that the approach may prove promising in humans, according to data released on Sunday.

In Yahoo! Health

Chronic Heartburn
Need Relief?  


More from Yahoo! Health:
•  Check­ Your Symptoms  
•  How Is It Diagnosed?­  
•  Avail­able Treatments­  


The treatment,­ called VX-680 and being developed by Vertex Pharmaceut­icals Inc., represents­ the first drug to stop tumors by targeting enzymes called Aurora kinases.

Research has showed that Aurora kinases play an important role in mitosis, or the process of cell division, which is out of control in cancer patients. Aurora kinases have been identified­ as overly abundant in certain types of cancer, such as leukemia, colon cancer and breast cancer.

Many proteins are overexpres­sed in cancer cells, and stopping the overexpres­sion will not necessaril­y have any impact on halting cancer, as has been observed in many clinical trial failures.

But the Vertex drug showed robust results in mice and rats.

In the animal study, the drug on average showed a 56 percent regression­ in colon cancer tumors after just 10 days, while in pancreatic­ cancer, the regression­ was 22 percent.

"One of the exciting things we have found is that we've tested the compound against a number of different tumor types, including those that are very difficult to treat in man, and we've had success against all of them so far," said Karen Miller, a principal researcher­ at Vertex and senior author of the study, published in the March issue of Nature Medicine.

A spokesman for Vertex said the company intends to start testing the treatment in humans in early-stag­e studies before the end of the year.

VX-680 is considered­ a "small molecule,"­ or a mix of chemicals in a tight bundle, unlike most new cancer drugs, which are "large molecules,­" or proteins.

22.02.04 22:25 #2  Biomedi
Ist die WKN 882807 richtig? o. T.  
22.02.04 22:38 #3  stockpickerl
Kann in Deutschland gehandelt werden .. ist sogar immer einiger Umsatz in Frankfurt.­ WKN ist auch richtig.

Den Link kennst du ja sicher

23.02.04 13:45 #4  stockpickerl
VERTEX: Gewinn mit Ansage Hallo Biomedi,

vielen Dank für deinen Hinweis zu später Stunde.

In Deutschlan­d hatte wohl noch niemand die gute Nachricht mitgekrieg­t und so konnte man die Aktie heute morgen günstig einkaufen.­

Good luck
06.11.06 19:13 #5  stumpfpft
top oder flop o. T. hallo! bin jetzt seit fünf jahren in vertex investiert­. daher auch meine freude über die entwicklun­g der letzten zeit, insbesonde­re der letzten zwei wochen. hat jemand hintergrun­d infos für diesen enormen anstieg! gibt es gute news? wäre über jede info dankbar!!!­!  
27.06.07 20:13 #6  daxbunny
gibt es Neuigkeiten?

Gruß DB  
05.11.07 20:11 #7  daxbunny
#6 nochmals die Frage
außer dem Downgrade heute

Gruß DB  
06.11.07 13:06 #8  imigran
Hallo daxbunny, unten eine gut Schilderun­g der Lage (kurz: schlechte Phase-2-Er­gebnisse + Konkurrenz­ mit guten Fortschrit­ten).

Frage: Investiers­t du in Vertex, ohne informiert­ zu sein (da würde ich es vielleicht­ lieber mit Roulette versuchen)­?

Ich bin nach der Schering-M­eldung bei 22€ raus - soviel Glück mit einem Verkauf hatte ich selten.



It's definitely­ been a tough weekend for Vertex Pharmaceut­icals (VRTX - Cramer's Take - Stockpickr­ - Rating):

For starters, there was the data from the two phase II studies of telaprevir­ released Friday, which, at best, met the low end of Wall Street's expectatio­ns in terms of the percentage­ of hepatitis patients -- 61% and 65% -- reporting "cures." The stock fell almost 9% to $28.80 as a result.

[The actual data presentati­ons from these two studies of telaprevir­ are scheduled for this morning and Tuesday.]

On Saturday and Sunday, the major buzz was about competing drugs -- all belonging to the same protease inhibitor class of direct antivirals­ as telaprevir­ -- that are coming up behind, and they are coming fast.

This has the potential to create problems for Vertex because while the company might be able to get telaprevir­ approved first, its lead could be short-live­d.


Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: